Pionyr Immunotherapeutics
Biotechnology Research • 
South San Francisco, California, United States • 51-100 Employees
Company overview
| Headquarters | 2 Tower Pl, Suite 800, South San Francisco, California 94080, US |
| Phone number | +16508256140 |
| Website | |
| SIC | 873 |
| Keywords | Translational Research, Immuno-Oncology, Myeloid Biology, Myeloid Tuning |
| Founded | 2015 |
| Employees | 51-100 |
| Socials |
Key Contacts at Pionyr Immunotherapeutics
Tony Brew
Snr Director & Head Of Information Technology, Cybersecurity & It Compliance
Yunfeng Yunfeng
Senior Director, Biostatistics
Marc Chamberlain
Senior Medical Director
Marc Chamberlain
Executive Medical Director
Pionyr Immunotherapeutics Email Formats
Pionyr Immunotherapeutics uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 48.2% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name}@company.com | john.doe@company.com | 48.2% |
{first name initial}{last name}@company.com | {first name initial}doe@company.com | 24.1% |
{first name}@company.com | john@company.com | 12.4% |
{last name}.{first name}@company.com | doe.john@company.com | 8.9% |
{first name}{last name}@company.com | johndoe@company.com | 6.4% |
About Pionyr Immunotherapeutics
In 2015, Pionyr Immunotherapeutics embarked on a journey to forge a new path in immuno-oncology for patients in need. We are a clinical stage company discovering and developing novel antibody therapeutics that dramatically alter the tumor microenvironment (TME) and enhance the body’s immune defense against cancer – with the potential to eliminate it. Pionyr's Myeloid Tuning™ cutting-edge technology is based on the discovery that “tuning” the tumor microenvironment to favor immune-activating cells and disable immune-suppressing cells improves the body’s ability to combat cancer, particularly in combination with checkpoint inhibitors. Additionally, Pionyr is building a pipeline of transmembrane and intracellular targets using our cutting-edge technologies and translational assays. Immuno-oncology is a complex field, which is why Pionyr has recruited a bold and growing team with extensive experience in immunology, immuno-oncology, target discovery, and immunotherapy development. Our “Pionyrs” are banded together by innovation, integrity, team empowerment, respect and one unified voice to translate meaningful science into promising opportunities for treating cancer.
Pionyr Immunotherapeutics revenue & valuation
| Annual revenue | $3,800,000 |
| Revenue per employee | $66,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $12,200,000 |
| Total funding | $275,000,000 |
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Pionyr Immunotherapeutics has 5 employees across 2 departments.
Departments
Number of employees
Funding Data
Explore Pionyr Immunotherapeutics's funding history, including investment rounds, total capital raised, and key backers.
France
United Kingdom
South Africa
Frequently asked questions
4.8
40,000 users
